-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Merafloxacin
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/91188-00-0.gif)
| Category | SARS-CoV |
| CAS | 91188-00-0 |
| Description | Merafloxacin is a fluoroquinolone antibacterial agent, which inhibits -1 frameshifting efficiency of beta coronaviruses including SARS-CoV-2. |
Product Information
| Synonyms | CI 934; CI-934; CI934 |
| IUPAC Name | 1-ethyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid |
| Molecular Weight | 379.40 |
| Molecular Formula | C19H23F2N3O3 |
| Canonical SMILES | CCNCC1CCN(C1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CC)F |
| InChI | InChI=1S/C19H23F2N3O3/c1-3-22-8-11-5-6-24(9-11)17-14(20)7-12-16(15(17)21)23(4-2)10-13(18(12)25)19(26)27/h7,10-11,22H,3-6,8-9H2,1-2H3,(H,26,27) |
| InChIKey | BAYYCLWCHFVRLV-UHFFFAOYSA-N |
| Boiling Point | 545.8ºC at 760mmHg |
| Purity | 95% |
| Density | 1.304g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 615 |
| Exact Mass | 379.17074793 |
| In Vitro | Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively. |
| PSA | 74.57000 |
| Target | IC50: 19.6 μM (SARS-CoV-2) |
| XLogP3-AA | -0.1 |
